International Journal of Contemporary Pediatrics
Soni M et al. Int J Contemp Pediatr. 2022 Oct;9(10):998-1002
http://www.ijpediatrics.com
pISSN 2349-3283 | eISSN 2349-3291

DOI: https://dx.doi.org/10.18203/2349-3291.ijcp20222435

Review Article

Pediatric multiple sclerosis on the rise

Mridul Soni*, Dilkanwal Singh Deol, Aditi Goyal

Department of Pediatrics, Shri Lal Bahadur Shastri Government Medical College, Himachal Pradesh, India

Received: 08 August 2022
Accepted: 06 September 2022

***Correspondence:**
Dr. Mridul Soni,
E-mail: mridulsoni29@gmail.com

ABSTRACT

The development of multiple sclerosis in children provides to have prophylactic and treatment problems, especially if the manifestations of the initial demyelinating episode mirror the acute disseminated encephalomyelitis. This disease which was once considered a rare occurrence has started to show more cases in the last few years. Magnetic resonance imaging seems to be an excellent diagnostic technique but it is limited because of the accuracy to identify acute disseminated encephalomyelitis from the initial bout of multiple sclerosis. Sophisticated magnetic resonance imaging methods could provide the needed precision to identify if the degradation and consistency of non-lesional matter can be differentiated for what happens as a core hallmark of multiple sclerosis. Even though the development of multiple sclerosis in infancy often forecasts a positive short-term outcome, several children become seriously impaired, whether physically or intellectually, and much more than fifty percent are anticipated to reach the secondary-progressive stage of the illness by the age of thirty years. Immunomodulatory treatments for multiple sclerosis and its therapeutic administration in adolescents may enhance long-term outcomes. Environmental and genetic variables, including viral infection, could be especially suitable for investigation in juvenile individuals with multiple sclerosis. Addressing the immunological effects of these exposures should offer insight into the early clinical manifestations and correct diagnosis of multiple sclerosis.

Keywords: Acute disseminated encephalomyelitis, Magnetic resonance imaging, Methylprednisolone, Cerebrospinal fluid, Adolescent female

INTRODUCTION

The most prevalent inflammatory demyelinating illness is multiple sclerosis. Whereas the illness has had a significant prevalence in adulthood, juvenile-onset multiple sclerosis was exceedingly rare in children but in recent years there has been an increase in cases of pediatrics multiple sclerosis worldwide and characteristics unique to this demographic have been found. This article will deal with the features of multiple sclerosis in childhood developmental states. In a COHORT study that was done by Absoud et al where a sample population of 4095 was selected in 2010, the research reached the conclusion that multiple sclerosis with onset in children is an uncommon condition that accounts for 3 to 10 percent of multiple sclerosis diagnoses and is been on the rise from the last sixty years.[1] Another research which lasted for three years between 2004 to 2007 conducted on Canadian children below the age of eighteen years showed than acquired demyelinating syndromes is 0.9 per 100,000.[2] Its prevalence varies from country to country and is predicted to be between 0.66 and 1.66 per 100,000 youngsters who are under eighteen years old.[2,3] A systemic analysis that was conducted by Banwell et al revealed that children under the age of 10 were indeed the most impacted, making up thirty percent of all pediatric-onset multiple sclerosis cases.[4] A COHORT study that was conducted between 1990 to 2003 in France with a sample population of 197 children affected with multiple sclerosis resulted in a conclusion that equal numbers of

girls and boys are affected below the age of 10 years, however, in the children greater than 10 years, a female prevalence was observed.[5] Based on this research another COHORT study was performed in Canada between 2004 and 2013 which found that puberty in the female population enhanced the central nervous system autoimmune activities which lead to the development of multiple sclerosis in the adolescent female population.[6] Criteria search for the clinical manifestations of multiple sclerosis conducted by Krupp et al compiling 150 study groups under the international pediatric multiple sclerosis study revealed the most frequent clinical manifestations were longitudinal tract dysfunction which was 65 percent and brainstem features at 37 percent as well as acute demyelinating encephalomyelitis at 34 percent and optic neuritis 15 percent.[7] Transverse myelitis is fairly uncommon and was found in only 7 percent, variations in clinical manifestations were found as per the age of progression of the disease.[7]

Diagnostic standards

The MacDonald 2010 standards for diffusion in time enabled pediatric-onset multiple sclerosis to be confirmed after only one attack, which is one of the main distinctions from the earlier 2007 guidelines.[8] One of the main peculiarities of pediatric-onset multiple sclerosis is the ability to incorporate acute disseminated encephalomyelitis demonstration as the first multiple sclerosis attacks.[8] Based on Krupp et al study the International Pediatric multiple sclerosis study group had set the gold standard diagnostic standards regarding pediatric-onset multiple sclerosis in 2012.[7]

Biological traits and indicators

A prospective study conducted by Ghezzi A et al in April 2002 revealed that the implementation of oligoclonal bands inside the multiple sclerosis criterion proved to be an excellent way to diagnose it based on biological indicators the study had 54 subjects in which they tested the oligoclonal bands for faster identification and found out that 57 percent of the control group could correctly be identified with that method.[9] In a prospective study which was conducted in the entire country of Germany comprising all the tertiary care hospitals for pediatrics from 2009 to 2011, it was found that the kids who once experienced an incident of multiple sclerosis before the age of ten years are about 27 percent more likely to develop severe long term complications compared to children who first experience multiple sclerosis after the age of ten who are 52 percent more likely.[10] Additionally, it was also demonstrated that neutrophil-like pleocytosis, instead of lymphocytes as in teenagers or adults, takes precedence in smaller kids, indicating the likely involvement of the body's immune response in this age group.[10] A very recent study conducted by Wong et al in 2018 was conducted on a sample population of 94 children with multiple sclerosis this research concluded that the cerebrospinal fluids sCD27 levels after the initial attack of demyelination were associated with multiple sclerosis diagnosis in children because of this, the sCD27 had been proven to be a clinically relevant quantitative marker while doing routine cerebrospinal fluids diagnostics.[11] The sCD27, a T cell stimulation marker, appears to be a reliable indicator of clinically confirmed multiple sclerosis in kids, as has already been shown in grownups.[11] The sCD27 from the cerebrospinal fluid is considerably higher among children having multiple sclerosis relative to non-acute disseminated encephalomyelitis among the 94 children in the study with severe demyelinating syndrome.[11] Additionally, in a very recent study from December 2020 by Calabresi et al had been demonstrated that it was elevated in individuals experiencing dissemination in spaces upon baseline magnetic resonance imaging and therefore was linked with increased immunoglobulin G levels as well as gadolinium enrichment.[12] Some other intriguing biomarker of pediatric-onset multiple sclerosis was light chain neurofilament, which was well-known in adulthood multiple sclerosis.[12] It had been shown that light chain neurofilament in cerebrospinal fluid was raised in both adult and pediatric multiple sclerosis and that greater light chain neurofilament levels in both adult and pediatric illnesses were related to a shorter time to the diagnosis.[12] According to the research on serum light chain neurofilament, this marker was elevated in pediatric multiple sclerosis patients as compared to healthy control individuals and it was associated with clinical and magnetic resonance imaging disease activity as well as therapy response.[12]

Magnetic resonance imaging (MRI)

To establish the diagnostic standards for pediatric-onset multiple sclerosis, many magnetic resonance imaging investigations have been conducted based on the COHORT study that was conducted for 12 years between 1900 to 2002 by Mikaeloff et al. The data concluded that the MRI was more indicative of pediatric-onset multiple sclerosis during the initial attack if there was at least one periventricular lesion, at least one thoracic vertebrae 1 hyposignal lesion then the diagnosis became further more clear.[13] Another study conducted in February 2011 portrayed that pediatricians should use the updated MacDonald 2010 criteria for children under the age of 12, given their poor specificity and sensitivity.[14] A retrospective study conducted in 2009 at a tertiary level center differentiating an adult MRI from that of a pediatric with multiple sclerosis noticed that at the time of onset, infants seemed to have more thoracic vertebrae 2 lesions than adults.[15] Additionally, a cross-sectional form of study concluded that the illness may start out with brain atrophy that even affects the deep gray matter areas.[16]

Development

In a COHORT study conducted at the Massachusetts General Hospitals in the United States of America in July

2001, the setting had one hundred patients with adulthood multiple and twenty-one patients with pediatric multiple sclerosis were in the study, it was observed that in comparison to adults, pediatric-onset multiple sclerosis seemed to be more active and had a higher recurrence rate, particularly in the first two years after the first attack.[17] After the first attack, full recovery without complications in multiple sclerosis of children was fairly typical for the younger age groups below ten years.[17] However, it was still possible for multiple sclerosis to evolve into a secondary progressive form and it had been observed that patients who first developed multiple sclerosis before the age of 18 take around ten years longer to evolve into this form, but they do so at younger ages than patients who first developed multiple sclerosis in adulthood.[18]

Environmental risk factors and genetics

Multiple sclerosis is a complex illness with familial and environmental risk factors and pediatric-onset multiple sclerosis gives a distinct chance to explore these aspects. Certainly, the interval between exposure to these variables and the development of the illness was smaller as well as the knowledge will indeed be simpler to get. Based on a COHORT study conducted in 2011 on 266 children and adulthood onset of multiple sclerosis had HLA-DRB1 mutations and these mutations have already been observed to become more prevalent in juvenile multiple sclerosis compared to control.[19] The research which included 188 children did gene research and found that the HLA-DRB1×15 allele was more common in childhood with multiple sclerosis than in adults with demyelinating illness.[20] Considering external cues, vitamin D plays a key role.[21] Indeed, serum vitamin D levels were highly connected with the likelihood of flare-ups in kids as well as an elevation of serum around ten nanograms per milliliter had now been correlated with something like a thirty-four percent reduction in recurrence incidence.[21] Furthermore, significant exposure to certain virus infections including such Epstein-Barr virus seemed to be more prevalent in childhood with multiple sclerosis than in the control group.[22]

Differential diagnosis

Given the case of pediatric-onset multiple sclerosis, clinical diagnoses of multiple sclerosis must be offered once all other alternative diagnoses have been eliminated. There are many remitting inflammatory demyelinating illnesses that can imitate pediatric-onset multiple sclerosis as well as mainly two of them, will have to be recognized sooner including such neuromyelitis optic spectrum disorders as well as antibodies against myelin oligodendrocyte glycoproteins (anti-MOG) connected with acute demyelinating diseases.[23] Anti-MOG antibodies have indeed been identified often in children with acute demyelinating diseases.[23] A recent COHORT study done in Europe on the relapsing anti-MOG positive acute demyelinating diseases demonstrated that standard multiple sclerosis therapy cannot be efficient in the pediatric population as it is for the adult population.[24] Therefore, anti-MOG antibodies should be sought at the commencement of any acute demyelinating diseases and additional care must be applied considering the ultimate diagnosis of multiple sclerosis in their presence. Systemic illnesses may potentially exhibit a neurological beginning with relapses and need to be identified using pediatric-onset multiple sclerosis as well as other genetic, metabolic, and neoplastic abnormalities.[24]

Cognitive and psychological effects

This impairment as determined either by the expanded disability status scale (EDSS) score is indeed not adaptable to pediatric-onset multiple sclerosis since it examines motor, coordination, visual, brainstem, sphincter and ambulation capabilities.[25] Children recover well following their flare-ups and seldom would exhibit an EDSS grade 4 throughout their follow-up.[25] But on the other side, cognitive impairments accompanying behavioral and cognitive effects might be noted. Many cross-sectional investigations have revealed cognitive impairment in almost one-third of juvenile multiple sclerosis patients, even in the early phases of the infection, compared to healthy controls.[25] Those cognitive domains primarily typically impaired in pediatric-onset multiple sclerosis are focus, recollection, the process of information coherence, language and visual and spatial incorporation. Exhaust and accompanying psychological issues may impair cognition. Fatigue is reported in 20 to 50 percent of pediatric patients and when anxiety and mood problems are linked with it, a decline in cognitive function may be noted.[26,27] These issues have a direct influence on the intensity of everyday routines and standards of living. Total statistics on the standard of living surveys are poorer relative to relatives, connected with neurological disability, length of sickness, MRI results and eyesight.[28]

Treatment

The management of chronic conditions involves large concentrations of steroids like methylprednisolone dose of thirty milligrams per kilogram per day not surpassing one gram over three to five days.[29] Oral reduction of steroids prednisone, one to two milligrams per kilogram per day is experimental.[29] Immunomodulator has been recommended by that the International Pediatric multiple sclerosis study group's working group that whenever a kid is identified as having pediatric-onset multiple sclerosis, long-term therapy may indeed be offered.[29] Immuno-modulators including such interferons as well as glatiramer acetate have been permitted to be used in kids above 12 years of age.[30] Even though there has been no controlled research, these immunotherapies have demonstrated comparable effectiveness and sensitivity with those of adulthood in various retrospectively worldwide investigations.[30] There is no clear agreement for such dosages of such therapeutic interventions that

can be used in kids, but for interferons, the prescribed amount seems to be the entire amount despite the age of a kid, which will then be indirectly adjusted depending upon that acceptance acquired during suggested dilutions of each interferon, the whole dosage will be administered in infants regardless of the user's age and therefore without titration.[31] Numerous oral medications are available that have been lately authorized for cases above eighteen years of age, including fingolimod, teriflunomide as well as dimethyl fumarate.[31] Such medications have been utilized to a limited extent in youngsters and lately many clinical studies in individuals below 18 years old with multiple sclerosis are underway.[31] Furthermore, the sensitivity is practically identical to what is reported in adulthood for these therapeutic medications and randomized experiments using teriflunomide plus dimethyl fumarate are presently conducted and further research is needed.

CONCLUSION

Pediatric onset multiple sclerosis has specificities in a contrast to adult multiple sclerosis, notably in juvenile and pre-pubertal kids. Brain damage is fairly common among children having multiple sclerosis, which needs particular care. This research on juvenile multiple sclerosis will assist to understand better the mechanism of the illness in light of the brief period in between possible triggers as well as the development of the disease. Several medical trials are presently ongoing with data that looks to become more hopeful than in grownups, which would enable improved treatment. Multiple sclerosis is a severe, autoimmune, inflammatory, demyelinating illness brain. Multiple sclerosis is recognized globally in the adolescent population, and it is generally identified at 15 years of age. The actual pathogenesis of multiple sclerosis has not been understood, however immunological, hereditary, and natural factors play an essential role in its progression, rendering it a complex illness. The illness in youngsters nearly often appears in the chronic and progressive type. The medication encompasses treatment of flare ups, including immunomodulatory and clinical therapy. The treatment of children with multiple sclerosis needs to be comprehensive and involve juvenile doctors and specialists, optometrists, psychiatrists, therapists, and if required, pediatric therapists and pharmacists. Management of flare ups requires the use of large injectable concentrations of corticosteroids, delivery of injectable immunoglobulins, including plasmapheresis. We review below the latest known facts relating to the pathogenesis and therapy choices in multiple sclerosis. Early initiation of immunomodulatory medication is advantageous in grownups, whereas additional research are required to confirm its usefulness in affected children. Consequently, pediatric multiple sclerosis currently offers a substantial challenge for both, the timely and proper identification, including its management.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Absoud M, Lim M, Chong W, DeGoede C, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Multiple Scler J. 2012;19(1):76-86.
2. Banwell B, Kennedy J, Sadovnick D, Arnold D, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232-9.
3. Ketelslegers I, Catsman-Berrevoets C, Neuteboom R, Boon M, Dijk K, Eikelenboom M, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol. 2012;259(9):1929-35.
4. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2007;6(10):887-902.
5. Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M. Prognostic factors for early severity in a childhood multiple sclerosis COHORT. Pediatrics. 2006;118(3):1133-9.
6. Ahn J, O'Mahony J, Moshkova M, Hanwell H, Singh H, Zhang M, et al. Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Multiple Sclerosis J. 2014;21(6):735-48.
7. Krupp L, Tardieu M, Amato M, Banwell B, Chitnis T, Dale R, et al. International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis J. 2013;19(10):1261-7.
8. Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.
9. Ghezzi A, Pozzilli C, Liguori M, Marrosu M, Milani N, Milanese C, et al. Prospective study of multiple sclerosis with early onset. Multiple Sclerosis J. 2002;8(2):115-8.
10. Reinhardt K, Weiss S, Rosenbauer J, Gärtner J, von Kries R. Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011). Eur J Neurol. 2014;21(4):654-9.
11. Wong Y, Vries R, Pelt E, Ketelslegers I, Melief M, Wierenga A, et al. T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. Multiple Sclerosis J. 2018;24(13):1715-24.

12. Calabresi P, Arnold D, Sangurdekar D, Singh C, Altincatal A, de Moor C, et al. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis J. 2020;27(10):1497-505.
13. Mikaeloff Y. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004;127(9):1942-7.
14. Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
15. Waubant E, Chabas D, Okuda D, Glenn O, Mowry E, Henry R, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66(8).
16. Aubert-Broche B, Fonov V, Ghassemi R, Narayanan S, Arnold D, Banwell B, et al. Regional brain atrophy in children with multiple sclerosis. Neuro Image. 2011;58(2):409-15.
17. Gorman M, Healy B, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1).
18. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N E J Med. 2007;356(25):2603-13.
19. Disanto G, Magalhaes S, Handel A, Morrison K, Sadovnick A, Ebers G, et al. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011;76(9):781-6.
20. Pelt E, Mescheriakova J, Makhani N, Ketelslegers I, Neuteboom R, Kundu S, et al. Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology. 2013;81(23):1996-2001.
21. Mowry E, Krupp L, Milazzo M, Chabas D, Strober J, Belman A, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol. 2010.
22. Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, Lehnert M, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006;67(11):2063-5.
23. Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat A, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017;264(9):1945-55.
24. Hacohen Y, Wong Y, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol. 2018;75(4):478.
25. Amato M. Cognitive impairment in early-onset multiple sclerosis. Arch Neurol. 1995;52(2):168.
26. Holland A, Graves D, Greenberg B, Harder L. Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. Child Neuropsychology. 2012;20(1):71-85.
27. Weisbrot D, Charvet L, Serafin D, Milazzo M, Preston T, Cleary R, et al. Psychiatric diagnoses and cognitive impairment in pediatric multiple sclerosis. Multiple Sclerosis J. 2013;20(5):588-93.
28. Mowry E, Loguidice M, Daniels A, Jacobs D, Markowitz C, Galetta S, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatr. 2009;80(7):767-72.
29. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis J. 2011;18(1):116-27.
30. Banwell B, Reder A, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472-6.
31. Chitnis T, Arnold D, Banwell B, Brück W, Ghezzi A, Giovannoni G, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N E J Med. 2018;379(11):1017-27.

Cite this article as: Soni M, Deol DS, Goyal A. Pediatric multiple sclerosis on the rise. Int J Contemp Pediatr 2022;9:998-1002.